Antiretrovirals in Development
- An Alternative NNRTI, TMC278, Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Another Integrase Inhibitor -- Elvitegravir (GS-9137) -- Progresses in Development (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- 79% of Treatment-Experienced Patients on MK-0518 Plus OBT Achieve Viral Load of Less Than 400 Copies at Week 16 (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Phase 3 Results of Two Key Trials of Maraviroc, the First-in-Class CCR5 Antagonist (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
HIV/HAART Complications
HIV Drug Resistance
HIV Prevention
Salvage Therapy
Treatment Strategies
- Coverage of the 14th Conference on Retroviruses and Opportunistic Infections (CROI) (April 2007)
To read PDF, click here
In Infectious Diseases in Corrections Report, from Infectious Diseases in Corrections Report
- New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Racial Disparities in HIV Diagnosis, Access to Care and Treatment Effects (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Interleukin-2 Expands Select CD4+ T-Cell Populations, but Has No Effect on HIV-Specific Immune Responses (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Virology and Immunology
Pre-Conference News